Trabec — Trabectedin
Trabectedin, derived originally from a marine organism, treats two genuinely rare cancer types — liposarcoma and leiomyosarcoma — in patients whose disease has spread and cannot be surgically treated after they've already tried other anticancer medications, positioning it as a specialty, later-line therapy for a small but consistently underserved patient population that sarcoma-treatment centers specifically seek out.
- Approved indications: Liposarcoma or leiomyosarcoma that has metastasized and is unresectable, in patients previously treated with certain other anticancer medicines; also indicated for recurrent ovarian cancer not responding to prior therapy
- Mechanism: An alkylating agent that binds specific nucleobases in tumor-cell DNA, triggering a cascade that disrupts the cell cycle and causes cancer-cell death
- Buyer profile: Specialist sarcoma-oncology centers and gynecologic-oncology programs, given the rarity of both its primary indications
- Treatment setting: Administered exclusively in hospital or clinic settings with staff specifically trained in cancer chemotherapy administration
Key Product Facts
1mg
Strength
Single-dose vial
Pack Size
Trabectedin
Active Ingredient
Oncology
Category
On Request
Availability
Trabectedin, derived originally from a marine organism, treats two genuinely rare cancer types — liposarcoma and leiomyosarcoma — in patients whose disease has spread and cannot be surgically treated after they've already tried other anticancer medications, positioning it as a specialty, later-line therapy for a small but consistently underserved patient population that sarcoma-treatment centers specifically seek out.
- Approved indications: Liposarcoma or leiomyosarcoma that has metastasized and is unresectable, in patients previously treated with certain other anticancer medicines; also indicated for recurrent ovarian cancer not responding to prior therapy
- Mechanism: An alkylating agent that binds specific nucleobases in tumor-cell DNA, triggering a cascade that disrupts the cell cycle and causes cancer-cell death
- Buyer profile: Specialist sarcoma-oncology centers and gynecologic-oncology programs, given the rarity of both its primary indications
- Treatment setting: Administered exclusively in hospital or clinic settings with staff specifically trained in cancer chemotherapy administration
- Hepatotoxicity: Significant risk requiring liver function testing before every treatment cycle — contraindicated in patients with pre-existing liver disease without dose adjustment
- Fertility impact: Can impair fertility in both men and women — fertility discussion recommended before starting treatment
- Vaccination caution: Should not be combined with recent yellow fever or other live vaccines
- Cardiac risk: Heart problems are a recognized serious side effect requiring monitoring
- Pregnancy: Unsafe, can cause severe birth defects — effective contraception required during treatment; men with partners of reproductive potential should use contraception for at least 5 months after the final dose
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C) with careful handling protocols
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Trabectedin used for?
Treats liposarcoma, leiomyosarcoma, and recurrent ovarian cancer that hasn't responded to prior treatment.
Get Trabectedin price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it affect fertility?
Yes, it can impair fertility in both men and women — a fertility discussion with the treating physician is recommended before starting.
Can it be given at home?
No, it's administered only in a hospital or clinic setting by staff trained in cancer chemotherapy.
Who supplies Trabectedin from India?
WHO-GMP certified manufacturer with full export documentation.
